Trailing Twelve Months Revenue Growth: Conduit Pharmaceuticals (CDT)

Public company logo of Conduit Therapeutics (CDT)

The lack of a commercial base and dependence on FDA/EMA regulators create risks visualized by the rolling annual sales growth trend; the 0.00 level reflects the current magnitude of this metric. An asset-light model involving license transfers ensures stability, while the reliability of drug delivery through clinics optimizes supply chains, minimizing financial threats for Conduit Pharmaceuticals (CDT).

Conduit Therapeutics (CDT) - Sales Growth YoY (TTM) from 11/23/2025 to 11/17/2026

Conduit Pharmaceuticals Inc (CDT) - metric breakdowns and financial figures

- current quotes and average value forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:Conduit Pharmaceuticals CDT
Original product of Conduit Pharmaceuticals Inc.

Patent protection for renal ischemia drugs and high FDA entry barriers provide Conduit Pharmaceuticals (CDT) with exceptional market isolation. By analyzing the year-over-year sales trajectory (TTM), investors assess trailing twelve-month revenue dynamics, which allows for the verification of cash flow stability and business predictability, eliminating the risk of asset overvaluation without accounting for the debt load.